CoChat
Sign Up
Cited by 95Nanoparticle-Based Drug DeliveryBarrier Structure and Function StudiesAdvanced Drug Delivery Systems

Personalized nanomedicine for CNS diseases

Open access
Kaushik, Ajeet, Jayant, Rahul Dev, Bhardwaj, Vinay, Nair, Madhavan·2018·Drug Discovery Today
DOI 10.1016/j.drudis.2017.11.010PMC PMC6897362
Open this paper in CoChat — free account

Abstract

Central nervous system (CNS) diseases are rapidly increasing globally. Currently used therapeutic agents to treat CNS diseases exhibit significant efficacy. However, the inability of these drugs to cross the blood-brain barrier (BBB) and invasiveness of the technologies to achieve localized drug delivery in disease-specific parts of the brain have thwarted pain-free and complete treatment of CNS diseases. Therefore, the safe, non-invasive, and targeted delivery of drugs to the brain using nanoparticles (NPs) is currently receiving considerable research attention. Here, we highlight advances in state-of-the-art personalized nanomedicine for the treatment of CNS diseases (with a focus on dementia), the related challenges, possible solutions, and prospects for nano-enabled personalized medicine.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.drudis.2017.11.010

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Nanotechnology can be used to improve the bioavailability of PUFA in the form of nanoliposomes.

    “Furthermore, nanotechnology can be used to improve the bioavailability of PUFA in the form of NL [34,37].”

    From Alzheimer's Disease: Treatment Strategies and Their Limitations. (2022) · cites this paper as [34]

    The Alzheimer’s disease section describes liposome-based nanocarriers for delivering other compounds, including curcumin. It does not say that nanoliposomes improve PUFA bioavailability; searches for PUFA, polyunsaturated fatty acids, and fatty-acid bioavailability found no such passage in our copy. (LLM, conf=0.79)

    Experimental — accuracy not yet measured

  • A growing number of studies report a restorative effect of nanoliposomes on cellular and animal models of neurological disorders, suggesting improved nanoparticle-mediated bioavailability in the central nervous system.

    “A growing number of studies report a restorative effect of NL on cellular and animal models of neurological disorders (stroke, Parkinson’s disease, AD) [34,35,36], suggesting improved NP-mediated bioavailability in the CNS.”

    From Alzheimer's Disease: Treatment Strategies and Their Limitations. (2022) · cites this paper as [34]

    The ‘Nanomedicine for Parkinson’s disease’ and ‘Nanomedicine for Alzheimer’s disease’ sections report improved outcomes in animal models treated with liposomal formulations. But the ‘Nanomedicine for stroke’ section reports good biodistribution for a liposome in rats and explicitly says its therapeutic performance needs further study. The copy therefore does not support a restorative effect of nanoliposomes across all the listed disorders and both cellular and animal models; page numbers were not provided. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 60

  1. [1]Nair M (2016) Getting into the brain: potential of nanotechnology in the management of NeuroAIDS. Adv. Drug Deliv. Rev 103, 202– 217 26944096 PMC4935582
  2. [2]Albert SM (2007) Projecting neurologic disease burden: difficult but critical. Neurology 68, 322– 323 17261676
  3. [3]Brew BJ and González-Scarano F (2007) HIV-associated dementia: an inconvenient truth. Neurology 68, 324– 325 17261677
  4. [4]Hirtz D (2007) How common are the ‘common’ neurologic disorders? Neurology 68, 326– 337 17261678
  5. [6]Kaushik A (2016) Advancements in nano-enabled therapeutics for neuroHIV management. Int. J. Nanomed 11, 4317 PMC5012604 27621624
  6. [7]Kaushik A (2014) The potential of magneto-electric nanocarriers for drug delivery. Expert Opin. Drug Deliv. 11, 1635– 1646 24986772 PMC4556109
  7. [9]Nair M (2013) Externally controlled on-demand release of anti-HIV drug using magneto-electric nanoparticles as carriers. Nat. Commun 4, 1707 23591874
  8. [10]Imaoka T (1998) Significant behavioral recovery in Parkinson’s disease model by direct intracerebral gene transfer using continuous injection of a plasmid DNA–liposome complex. Hum. Gene Ther. 9, 1093– 1102 9607420
  9. [11]Jain K (2009) Role of nanobiotechnology in the development of personalized medicine. Nanomedicine 4, 249– 252 19331532
  10. [12]Jain KK (2008) The Handbook of Nanomedicine. Springer
  11. [13]Jain KK (2017) The Handbook of Nanomedicine (3rd edn.), Springer
  12. [14]Lammers T (2012) Personalized nanomedicine. Clin. Cancer Res. 18, 4889– 4894 22829203
  13. [15]Mura S and Couvreur P (2012) Nanotheranostics for personalized medicine. Adv. Drug Deliv. Rev 64, 1394– 1416 22728642
  14. [16]Theek B (2014) The theranostic path to personalized nanomedicine. Clin. Transl. Imaging 2, 66– 76 24860796 PMC4031631
  15. [17]Tietjen GT and Saltzman WM (2015) Nanomedicine gets personal. Sci. Transl. Med 7 314fs347 26582895
  16. [18]Vizirianakis IS (2011) Nanomedicine and personalized medicine toward the application of pharmacotyping in clinical practice to improve drug-delivery outcomes. Nanomedicine 7, 11– 17 21094279
  17. [19]Janowski M (2012) Personalized nanomedicine advancements for stem cell tracking. Adv. Drug Deliv. Rev 64, 1488– 1507 22820528 PMC3477295
  18. [20]Yu D (2017) Multiplexed RNAi therapy against brain tumor-initiating cells via lipopolymeric nanoparticle infusion delays glioblastoma progression. Proc. Natl. Acad. Sci. U. S. A 114, E6147– E6156 28696296 PMC5544292
  19. [21]Kaushik A (2017) Advances in Personalized Nanotherapeutics. Springer
  20. [22]Wong HL (2012) Nanotechnological advances for the delivery of CNS therapeutics. Adv. Drug Deliv. Rev 64, 686– 700 22100125
  21. [24]Kaushik A (2016) Magnetically guided central nervous system delivery and toxicity evaluation of magneto-electric nanocarriers. Sci. Rep 6, 25309 27143580 PMC4855156
  22. [25]Hamburg MA and Collins FS (2010) The path to personalized medicine. N. Engl. J. Med 2010, 301– 304 20551152
  23. [26]Fornaguera C and García-Celma MJ (2017) Personalized nanomedicine: a revolution at the nanoscale. J. Personal. Med 7, 12 PMC5748624 29023366
  24. [27]Kaushik A (2016) Nano-biosensors to detect beta-amyloid for Alzheimer’s disease management. Biosens. Bioelectron 80, 273– 287 26851586 PMC4786026
  25. [29]Yang Z (2010) Pharmacological and toxicological target organelles and safe use of single-walled carbon nanotubes as drug carriers in treating Alzheimer disease. Nanomedicine 6, 427– 441 20056170
  26. [30]Jaruszewski KM (2012) Chitosan enhances the stability and targeting of immuno-nanovehicles to cerebro-vascular deposits of Alzheimer’s disease amyloid protein. Nanomedicine 8, 250– 260 21704598 PMC3767177
  27. [31]Mathew A (2012) Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer’s disease. PLoS One 7, e32616 22403681 PMC3293842
  28. [32]Lazar AN (2013) Curcumin-conjugated nanoliposomes with high affinity for Aβ deposits: possible applications to Alzheimer disease. Nanomedicine 9, 712– 721 23220328
  29. [34]Cheng KK (2015) Curcumin-conjugated magnetic nanoparticles for detecting amyloid plaques in Alzheimer’s disease mice using magnetic resonance imaging (MRI). Biomaterials 44, 155– 172 25617135
  30. [35]Bernardi A (2012) Indomethacin-loaded lipid-core nanocapsules reduce the damage triggered by A(1–42 in Alzheimer’s disease models. Int. J. Nanomed 7, 4927– 4942 PMC3446842 23028221
  31. [36]Elnaggar YS (2015) Novel piperine-loaded Tween-integrated monoolein cubosomes as brain-targeted oral nanomedicine in Alzheimer’s disease: pharmaceutical, biological, and toxicological studies. Int. J. Nanomed 10, 5459 PMC4556290 26346130
  32. [37]Balducci C (2014) Multifunctional liposomes reduce brain β-amyloid burden and ameliorate memory impairment in Alzheimer’s disease mouse models. J. Neurosci 34, 14022– 14031 25319699 PMC4198543
  33. [40]Lee HJ (2011) Amine-modified single-walled carbon nanotubes protect neurons from injury in a rat stroke model. Nat. Nanotechnol 6, 121– 125 21278749 PMC4113082
  34. [42]Santos T (2016) Nanomedicine approaches to modulate neural stem cells in brain repair. Trends Biotechnol. 34, 437– 439 26917252
  35. [43]Silva-Candal A (2017) Vectorized nanodelivery systems for ischemic stroke: a concept and a need. J. Nanobiotechnol 15, 30 PMC5387212 28399863
  36. [44]Shcharbina N (2013) Nanomaterials in stroke treatment. Stroke 44, 2351– 2355 23715957
  37. [45]Martín Giménez VM (2017) Nanomedicine applied to cardiovascular diseases: latest developments. Ther. Adv. Cardiovasc. Dis 11, 133– 142 28198204 PMC5933544
  38. [46]Alexandrov AV (2004) Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N. Engl. J. Med 351, 2170– 2178 15548777
  39. [47]Higgins P (2011) Nanomedicine: nanotubes reduce stroke damage. Nat. Nanotechnol 6, 83– 84 21278751
  40. [48]Moon SU (2012) Carbon nanotubes impregnated with subventricular zone neural progenitor cells promotes recovery from stroke. Int. J. Nanomed 7, 2751 PMC3373297 22701320
  41. [49]Campos-Martorell M (2016) Charge effect of a liposomal delivery system encapsulating simvastatin to treat experimental ischemic stroke in rats. Int. J. Nanomed 11, 3035 PMC4935044 27418824
  42. [50]Argibay B (2017) Intraarterial route increases the risk of cerebral lesions after mesenchymal cell administration in animal model of ischemia. Sci. Rep 7, 40758 28091591 PMC5238501
  43. [51]Newland B (2016) Targeting delivery in Parkinson’s disease. Drug Discov. Today 21, 1313– 1320 27312875
  44. [52]Benabid AL (2009) Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson’s disease. Lancet Neurol. 8, 67– 81 19081516
  45. [53]Yue K (2012) Magneto-electric nano-particles for non-invasive brain stimulation. PLoS One 7, e44040 22957042 PMC3434207
  46. [54]da Rocha Lindner G (2015) Improved neuroprotective effects of resveratrol-loaded polysorbate 80-coated poly (lactide) nanoparticles in MPTP-induced Parkinsonism. Nanomedicine 10, 1127– 1138 25929569
  47. [55]Fernández M (2011) An effective novel delivery strategy of rasagiline for Parkinson’s disease. Int. J. Pharm 419, 271– 280 21807080
  48. [56]Haney MJ (2015) Exosomes as drug delivery vehicles for Parkinson’s disease therapy. J. Control. Release 207, 18– 30 25836593 PMC4430381
  49. [57]Zhao Y (2014) GDNF-transfected macrophages produce potent neuroprotective effects in Parkinson’s disease mouse model. PLoS One 9, e106867 25229627 PMC4167552
  50. [58]Herrán E (2014) Increased antiparkinson efficacy of the combined administration of VEGF-and GDNF-loaded nanospheres in a partial lesion model of Parkinson’s disease. Int. J. Nanomed 9, 2677 PMC4043720 24920904
  51. [59]Zhang Y (2003) Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum. Gene Ther. 14, 1– 12 12573054
  52. [61]López T (2011) Treatment of Parkinson’s disease: nanostructured sol-gel silica-dopamine reservoirs for controlled drug release in the central nervous system. Int. J. Nanomed 6, 19– 31 PMC3025590 21289978
  53. [62]Kaushik A (2017) Investigation of ac-magnetic field stimulated nanoelectroporation of magneto-electric nano-drug-carrier inside CNS cells. Sci. Rep 7, 45663 28374799 PMC5379488
  54. [63]Ferrari M (2009) Nanomedicine and society. Clin. Pharmacol. Ther 85, 466– 467 19381150
  55. [64]Sanhai WR (2008) Seven challenges for nanomedicine. Nat. Nanotechnol 3, 242– 244 18654511
  56. [65]Nordmann A and Rip A (2009) Mind the gap revisited. Nat. Nanotechnol 4, 273– 274 19421202
  57. [66]Kranz C (2011) Analytical Challenges in Nanomedicine. Springer 21225249
  58. [67]Muldoon L (2006) Imaging and nanomedicine for diagnosis and therapy in the central nervous system: report of the eleventh annual Blood–Brain Barrier Disruption Consortium meeting. Am. J. Neuroradiol 27, 715– 721 16552023 PMC7976977
  59. [68]Baun A and Hansen SF (2008) Environmental challenges for nanomedicine. Nanomedicine 3, 605– 608 18817463
  60. [69]Saraiva (2016) Nanoparticle-mediated brain drug delivery: Overcome blood-brain-barrier to treat neurodenerative disease. J. Control. Release 235, 34– 47 27208862

Cited by

Sorted by citations

Authors
Kaushik, A., Jayant, R. D., Bhardwaj, V., & Nair, M.
Affiliations
  • Florida International University (US)
  • Rutgers, The State University of New Jersey (US)
Corresponding author
Nair, Madhavan
ORCID
Venue
Drug Discovery Today
Publisher
Elsevier BV
Published
2018-05
Volume
23
Issue
5
Pages
1007-1015
ISSN
1359-6446 (ISSN-L)
DOI
10.1016/j.drudis.2017.11.010
PMC
PMC6897362
OpenAlex
W2769866181
Cited by
95
References
6
Citations by year
2026: 3 · 2025: 6 · 2024: 15 · 2023: 11 · 2022: 12 · 2021: 18 · 2020: 14 · 2019: 7 · 2018: 9
FWCI
0.59
Type
journal article
Language
en
Open access
Licence
Locations
  • Drug Discovery Today (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
NIH grants (RO1DA042706, R01DA040537, RO1DA037838, RO1DA034547)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
Keywords
personalized nanomedicine, central nervous system disorders, blood-brain barrier, brain drug delivery, nanoparticles, dementia, targeted drug delivery, non-invasive drug delivery
MeSH terms
Animals, Central Nervous System Diseases, Humans, Nanomedicine, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review